The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …

Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …

Background: Non-small cell lung cancer (NSCLC) has a poor prognosis despite
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

Objectives Bevacizumab and erlotinib inhibit different tumour growth pathways, and both
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …

The meta-analysis evaluated the efficacy and safety of chemotherapy or tyrosine kinase
inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors …

Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …

Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …

We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …